Compare Heron Therapeutics Inc (HRTX) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Okta, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Okta, Inc. trades at $222.99 (market cap $38.50B). The key difference: Okta, Inc. is far larger — about 566.1× Heron Therapeutics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Okta, Inc. for 44 Days on average.
| HRTX | OKTA | |
|---|---|---|
Market Cap | $68.01M | $38.50B |
Volume | 1,891,941 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $1.49 | $220.21 |
52-Week Low | $0.27 | $62.93 |
Typical Hold Time | 35 Days | 44 Days |
Enterprise Value | $174.75M | $36.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
OKTA trades at $218.00, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $2.61 billion in 2025 with a net income turnaround to $28 million. Recent earnings beats and positive analyst sentiment (73.58% buy ratings) highlight momentum, though high valuation ratios like a P/E of 131.33 pose concerns. Key developments include AI security initiatives unveiled at Oktane 2026, driving media attention.
Outlook: OKTA's focus on AI agent security and identity management positions it for growth in cybersecurity, but elevated valuations and insider selling require caution. Risks include competitive pressures and execution challenges. The consensus price target of $201.30 suggests modest downside, yet innovation catalysts offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
